Search

Your search keyword '"Kirsten Vang Nielsen"' showing total 2 results
Start Over Author "Kirsten Vang Nielsen" Journal acta oncologica
2 results on '"Kirsten Vang Nielsen"'

1. The value ofTOP2Agene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D

Author

Helle Charlotte Knudsen, Bent Ejlertsen, Henning T. Mouridsen, Susanne Møller, Jan Trøst Jørgensen, Ann Knoop, and Kirsten Vang Nielsen

Subjects
Oncology, Receptor, erbB-2, medicine.medical_specialty, Cyclophosphamide, Receptor, ErbB-2, Gene Dosage, Breast Neoplasms, Disease-Free Survival, law.invention, Breast cancer, Randomized controlled trial, Antigens, Neoplasm, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, medicine, Clinical endpoint, Humans, Radiology, Nuclear Medicine and imaging, Poly-ADP-Ribose Binding Proteins, skin and connective tissue diseases, In Situ Hybridization, Fluorescence, Epirubicin, Retrospective Studies, Gynecology, business.industry, Hematology, General Medicine, medicine.disease, DNA-Binding Proteins, Clinical trial, DNA Topoisomerases, Type II, Methotrexate, Tumor Markers, Biological, Fluorouracil, DNA Topoisomerases, Type II, Eukaryotic, Multivariate Analysis, Biomarker (medicine), Female, business, medicine.drug
Abstract

Udgivelsesdato: 2008 BACKGROUND: Previous analyses of TOP2A and HER2 in the Danish Breast Cancer Coopererative Group (DBCG) trial 89D suggested that TOP2A amplifications and possible also deletions are predictive markers for the effect of adjuvant epirubicin in patients with primary breast cancer. We present an updated and extended statistical analysis, requested for IVD-labeling of TOP2A testing. MATERIAL AND METHODS: In the DBCG trial 89D 980 Danish patients were randomly assigned to nine cycles of intravenous CMF (cyclophosphamide, methotrexate, and fluorouracil) or CEF (cyclophosphamide, epirubicin, and fluorouracil). Archival tumor tissue was collected retrospectively from 806 of these patients in a prospectively designed, biological sub-study, and was successfully analyzed for TOP2A aberrations and HER2 status in 773 samples (96%). Recurrence-free survival (RFS) was the primary endpoint. RESULTS: TOP2A aberrations (amplifications and deletions) were significantly associated with shorter RFS (p

Published
2008

2. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes

Author

Andreas Schønau, Kirsten Vang Nielsen, Karen Ege Olsen, Helle Charlotte Knudsen, Bent Ejlertsen, Jens Overgaard, Ann Knoop, Eva Balslev, and Birgitte Bruun Rasmussen

Subjects
Adult, Breast Neoplasms, TOP2A Gene, Biology, Sensitivity and Specificity, HercepTest, Breast cancer, Predictive Value of Tests, Gene duplication, medicine, Humans, Genetic Predisposition to Disease, Radiology, Nuclear Medicine and imaging, Gene, In Situ Hybridization, Fluorescence, Aged, Regulation of gene expression, Predictive marker, medicine.diagnostic_test, Biopsy, Needle, Gene Amplification, Hematology, General Medicine, Genes, erbB-2, Middle Aged, Prognosis, medicine.disease, Immunohistochemistry, Molecular biology, Gene Expression Regulation, Neoplastic, DNA Topoisomerases, Type II, Oncology, Cancer research, Female, Gene Deletion, Fluorescence in situ hybridization
Abstract

New strategies for improving treatment of patients with breast carcinoma have focused on the HER2 oncoprotein with regard to response to traditional therapy regimes and the effect of a new drug specifically directed against the protein. Furthermore, the status of the topoisomerase IIalpha (TOP2A) gene has been suggested as a predictive marker of anthracycline treatment. In this study of 120 tumours, immunohistochemically detected HER2 overexpression with HercepTest has been compared to the HER2 gene amplification investigated with a new HER2 probe for fluorescence in situ hybridization (FISH). In addition, the HercepTest was evaluated as a screening tool for choosing cases for FISH investigation of TOP2A gene aberrations. The HercepTest score 3+ identified HER2 gene amplification in 27 of 30 amplified tumours (sensitivity of 0.90) with a false-negative rate of 0.10 and a false-positive rate of 0.06. TOP2A gene amplification or deletion was found in 20 cases. Sixteen (80%) of these carcinomas were in the HercepTest 3+ group, but four tumours had alterations in the TOP2A gene with normal HER2 status. Traditionally, in the FISH technique the result has been based on counting 60 cells. However, we found that a much less time-consuming method of counting 60 signals gave equally good results.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results